Rafael Holdings, Inc. (RFL) · Oct 29, 2026 · Other events
NDA submitted — NDA submitted; primary endpoint p=0.19, background-therapy subgroup p=0.046
Rafael Holdings filed an FDA NDA for remibetadex, moving its lead drug into review while the pivotal trial’s main endpoint remains statistically inconclusive.
Rafael Holdings is a biotech holding company now centered on remibetadex, its lead treatment for Niemann-Pick Disease Type C, and is moving from pivotal-trial execution toward regulatory review. The September 30, 2026 topline release had already disclosed the failed primary endpoint and the plan to submit an NDA in the fourth quarter, so today’s submission is a meaningful execution milestone but not a new clinical readout.
The filing advances the program into the FDA process, but does not resolve the central efficacy question. Cyclo Therapeutics submitted the NDA seeking approval for adult and pediatric patients from birth. 〔0〕 The next regulatory gate is whether the FDA accepts the application for filing and grants Priority Review; that decision is expected within 60 days of receipt. 〔1〕
The evidence package is genuinely mixed rather than cleanly supportive. The pivotal study showed a 64% directional slowing of progression, but the primary endpoint did not reach statistical significance at p=0.19. 〔2〕 A prespecified subgroup representing about 83% of participants did reach statistical significance, with 71% relative slowing and p=0.046, while the survival analysis supplied additional supportive evidence in infantile-onset patients. Those positives help justify the application, but the failed primary endpoint leaves approval dependent on the FDA’s judgment of the totality of the evidence rather than on an unambiguous Phase 3 win.
| Measure | Phase 3 / analysis | Comparator |
|---|---|---|
| Primary-endpoint progression slowing (Financial Results) | 64% | p=0.19 |
| Background-therapy subgroup slowing (Financial Results) | 71% | p=0.046 |
| Infantile-onset mortality-risk reduction (Overall Survival Analysis) | 85% | p=0.044 |
| Serious adverse events (Safety Results) | 35.9% | 16.7% placebo |
Safety adds another regulatory complication. The company reports no new safety signals and says remibetadex was generally well tolerated, but serious adverse events were more frequent with treatment than placebo at 35.9% versus 16.7%. 〔3〕 That does not prevent an NDA submission, but it gives regulators another issue to weigh alongside the non-significant primary endpoint.
The filing is strategically important but only partly surprising. It converts a previously announced Q4 submission plan into a completed regulatory action and introduces the nonproprietary name remibetadex, while the underlying clinical results were already public. An approval could also create eligibility for a Rare Pediatric Disease Priority Review Voucher, but that remains contingent on approval and is not current capital.
Bottom line: This moves Rafael’s lead asset from clinical development into formal FDA review, keeping the program alive. It is not a clean positive because the NDA rests on supportive subgroup and survival data against a primary endpoint that missed statistical significance and a higher serious-adverse-event rate.
FDA filing and Priority Review decision within 60 days
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!